Inovio Pharmaceuticals (INO) has risen sharply, recording gains of 0.79% in the past 4 weeks. However, the stock has corrected -9.14% in the past 1 week, providing a good buying opportunity on dips. Inovio Pharmaceuticals (INO) : During the past 4 weeks, traders have been relatively bearish on Inovio Pharmaceuticals (INO), hence the stock is down -0.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.19% relative to the S&P 500.
The stock has recorded a 20-day Moving Average of 4.71% and the 50-Day Moving Average is 8.19%. Inovio Pharmaceuticals (NASDAQ:INO): On Fridays trading session , Opening price of the stock was $8.91 with an intraday high of $9.05. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.83. However, the stock managed to close at $8.95, a loss of 0.11% for the day. On the previous day, the stock had closed at $8.96. The total traded volume of the day was 613,904 shares.
The company Insiders own 9.9% of Inovio Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 7.56% . Institutional Investors own 26.98% of Inovio Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 7.56%. Also, Equity analysts at the Brokerage firm Maxim Group downgrades its rating on Inovio Pharmaceuticals (NASDAQ:INO). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 9, 2016.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.